Clicky

Immuron Limited  (IMC)

Description: Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.


Keywords: Medicine Pharmaceutical Biopharmaceutical Disease Diabetes Infectious Diseases Travel Antibodies Infection Hepatitis Colitis Steatohepatitis Gram Positive Bacteria Clostridioides Difficile Clostridium Difficile Clostridiaceae Colostrum

Home Page: www.immuron.com.au

IMC Technical Analysis

62 Lygon Street
Carlton, VIC 3053
Australia
Phone: 61 3 9824 5254


Officers

Name Title
Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA Chief Exec. Officer
Dr. Jerry Kanellos Ph.D. Chief Operating Officer
Mr. Phillip Allen Hains BBus(Acc), CA, MBA CFO & Company Sec.
Mr. David Lyon Head of Marketing
Dr. Dan Ruben Peres Chief Medical Officer
Mr. Flavio Palumbo Chief Commercial Officer

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7863
Price-to-Sales TTM: 23.2206
IPO Date:
Fiscal Year End: June
Full Time Employees: 5
Back to stocks